Non-target metabolomics pfofiling of neuromyelities optica spectrum disorder

Abstract

Objective To investigate the metabolomics characteristic of neuromyelities optica spectrum disorder (NMOSD) in plasma and cerebrospinal fluid. Methods Ultra high performance liquid chromatography-mass spectrometry (UHPLC-MS) was used to identify plasma metabolites in 16 patients with NMOSD and 8 healthy controls. At the same time, the identification of metabolites in cerebrospinal fluid of 8 NMOSD patients and 5 healthy controls was completed. Differential metabolites screening and metabolomic pathway analysis were performed by diversified data analysis methods. Results Compared with healthy control group, the content of 8 substances such as Cis.8.11.14.Eicosatrienoic acid in the plasma of NMOSD patients was increased.The content of 8 substances such as L-glutamine acid were decreased. There was no significant difference in the metabolites between Aquaporin 4 (AQP-4) antibody positive and negative NMOSD plasma. The content of 6 substances such as 3-hydroxybutyric acid in cerebrospinal fluid of patients with NMOSD was reduced. Conclusions The distribution of metabolites in plasma between NMOSD patients and healthy controls was significantly different. There was no significant difference in metabolites between AQP-4 antibody positive and negative NMOSD plasma. There are some differences in metabolites between cerebrospinal fluid of NMOSD patients and healthy controls. A variety of amino acid abnormalities, sphingomyelin dysfunction, energy metabolism and mitochondrial dysfunction were involved in the pathogenesis of NMOSD. Key words: Neuromyelitis optica/BL/CF; Chromatography, high pressure liquid; Mass spectrometry; Metabolomics